Tempus AI

We’re excited to be partnering with United Therapeutics Corporation to develop and investigate AI-based medical device software to detect patients at risk of having undiagnosed pulmonary hypertension (PH). Together with UT, we plan to implement this prospective clinical study at up to 60 centers to evaluate the clinical impact of this technology and gain new insights into the detection and diagnosis of PH. Read more: https://tempus.co/3XFC0a4

Join us on Tuesday, July 9th at 1:00 p.m. CT for an upcoming #webinar, “Harnessing the Power of AI: Optimizing Workflows & Enhancing Testing Across the Cancer Care Continuum.” Tempus speakers, Ezra Cohen, MD, FASCO, Kate Sasser, PhD, and Halla Nimeiri, MD, will discuss the latest advancements in our AI & technology, as well as our recent expansion into the MRD and monitoring space, which are helping to streamline efficiencies in clinical practices and research processes. Register here: https://tempus.co/4ctgf1f

An analysis of 15,000 de-identified Tempus nP PGx patient records, recently published in Molecular Psychiatry, revealed that 65% of patients had CYP2D6 and CYP2C19 phenotypes actionable for medication prescribing. More than half of the top 25 most frequently prescribed medications in psychiatry are metabolized by CYP2D6 and CYP2C19, emphasizing the importance of these findings. Access the full manuscript here: https://tempus.co/3VMYjZW

👩⚕️ 2000+ connected healthcare providers.  🔬 7.7M+ de-identified records for research.  🤖 60 AI algorithms deployed clinically. ⬇️ It’s why Tempus AI is leading the way in data-driven precision medicine. #NasdaqListed

🎉 Welcome to the Nasdaq family, Tempus AI! 🎉 🤖 $TEM harnesses the power of data and AI to drive precision medicine forward. Now they’re officially #NasdaqListed!

Thank you to all of our patients and physician and research partners for your collective commitment to our mission of improving patient outcomes. This is just the beginning. 

Taking a moment to acknowledge this milestone of becoming a public company. This is just one step forward as we advance our mission of helping patients live longer and healthier lives. Explore how we’re bringing AI to healthcare: www.tempus.com 

Join us for an upcoming #webinar, “ADCs in focus: The next generation of precision medicine in oncology” on June 24 at 1 PM CT. Industry leaders Daniel Johnson, MD, Funda Meric-Bernstam, MD, Kellogg Parsons, MD, MHS, FACS and Kate Sasser, PhD will discuss the emergence of resistance mutations in first-gen #ADCs, evaluate combination strategies with immune checkpoint inhibitors (ICIs), and assess next-gen targets and technologies. Register here: https://tempus.co/3KI29x7

We’re excited to share that Dr. Victoria Villaflor from City of Hope is one of the first to activate Tempus’ Phoenix study. Phoenix is a multi-institutional, biomarker profiling study in front line metastatic Head and Neck Squamous Cell Carcinoma (HNSCC). As part of the study, enrolled patients will undergo molecular testing at various points throughout their journey, from metastatic diagnosis through progression, to support research for HNSCC. Learn more: https://tempus.co/Phoenix

At Tempus, we are passionate about moving the needle in neuro-psychiatry by empowering clinicians through pharmacogenomic testing which delivers more personalized treatment options for those struggling with their mental health. Tempus stands out in the field of PGx testing by continuously integrating the latest FDA, CPIC and expert consortia guidelines for 110+ medications into our report. You can learn more here: https://tempus.co/4bPyopU